LONDON AND HONG KONG, Jan 11, 2023 - (ACN Newswire via SEAPRWire.com) - Prenetics Global Limited (NASDAQ: PRE) a leader in genomic and diagnostic testing, today announced that ACT Genomics, a company which Prenetics recently acquired a majority stake in, has received clearance from the U.S. Food and Drug Administration (FDA) for ACTOnco, the company's comprehensive genomic profiling test for solid tumors. ACTOnco is intended for use by healthcare professionals to help them inform clinical management decisions in accordance with professional guidelines for cancer patients with solid tumors. This is the first and only Asia-based company to receive FDA clearance for a comprehensive genomic profiling test. ACTOnco is a diagnostic test which:-- provides a comprehensive genomic profiling test that looks at 440 cancer-associated genes;-- provides information to help guide clinical management decisions on the use of targeted oncology therapies, including immunotherapies;-- is intended as a pan-cancer test including breast, colon, endometrial, lung, and other cancers;-- is an FDA-cleared platform for comprehensive genomic profiling assay development for biopharma companies developing precis...